Novo Nordisk Proposes Lars Rebien Sørensen as Interim Chair Amidst Board Shake-Up

By / / Breaking News

Key Takeaways

  • Novo Nordisk A/S ([NOVO B](/stock/NOVO B)) has proposed Lars Rebien Sørensen as the new interim Chair of its board of directors, effective until the next Annual General Meeting (AGM).
  • The nomination follows a significant board overhaul, with current Chair Helge Lund and six other board members stepping down due to recent market challenges and a decline in the company's share price since mid-2024.
  • The Novo Nordisk Foundation, the majority voting shareholder of Novo Nordisk through Novo Holdings A/S, initiated the changes to increase its representation and influence on the board.
  • Lars Rebien Sørensen brings extensive experience, having previously served as CEO of Novo Nordisk from 2000 to 2016 and currently chairs the Novo Nordisk Foundation and Novo Holdings A/S.

Danish pharmaceutical giant Novo Nordisk A/S ([NOVO B](/stock/NOVO B)) announced a significant leadership transition, proposing Lars Rebien Sørensen as the new interim Chair of its board of directors. The appointment is intended to be temporary, lasting until the company's next Annual General Meeting. This move comes as the current Chair, Helge Lund, and six other board members are stepping down, signaling a major shake-up in the company's governance.

The changes are reportedly a direct response to recent market challenges and a notable decline in Novo Nordisk's share price since mid-2024. The Novo Nordisk Foundation, which controls the majority of voting shares in the company through its investment arm Novo Holdings A/S, has actively sought to increase its representation and influence on the board, leading to these executive shifts.

Lars Rebien Sørensen is a highly experienced figure in the pharmaceutical industry, having served as the President and CEO of Novo Nordisk A/S from 2000 to 2016. He currently holds the position of Chair for both the Novo Nordisk Foundation and Novo Holdings A/S, making him a pivotal figure in the broader Novo Group. His deep understanding of the company and the sector is expected to provide stability during this transitional period.

In addition to the board changes, Lars Fruergaard Jørgensen will also step down from his role as CEO of Novo Nordisk A/S. He has agreed to remain in the position for a transitional period to ensure a smooth handover to his successor, for whom a search is currently underway. The foundation believes these leadership adjustments are in the best interest of the company and its shareholders, aiming to optimally position Novo Nordisk for future growth and to realize its full potential.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top